Does Illinois Medicaid Cover Ozempic, Wegovy or Zepbound? Diabetes Yes, Weight Loss No

Yes, for type 2 diabetes. As of November 2026, Illinois Medicaid’s drug list includes Ozempic, with the tablets preferred (prior authorization required) and the pen non-preferred, but neither Ozempic nor any other GLP-1 is covered for weight loss alone.^[1] The same list does cover Wegovy to lower heart risk or treat the liver disease MASH, and Zepbound for sleep apnea, as non-preferred drugs that need approval.^[1]

Does Illinois Medicaid cover Ozempic?

Yes, as a diabetes drug. The Illinois list splits Ozempic by form: Ozempic tablets are preferred with prior authorization, while the Ozempic pen is non-preferred.^[1] Trulicity, Victoza and generic liraglutide are preferred with no prior authorization flag on the list, and Mounjaro, Byetta and generic exenatide are non-preferred.^[1] For most people starting a diabetes GLP-1 through Medicaid, that makes Trulicity, Victoza or liraglutide the simplest first choice, with Ozempic tablets next.

Rybelsus still has a preferred row, but Novo Nordisk is discontinuing it and Illinois told prescribers in May 2026 that switching to Ozempic tablets needs a new prescription and a new prior authorization.^[1][7] Our article on the end of Rybelsus covers the switch.

Will Illinois Medicaid pay for Wegovy or Zepbound to lose weight?

No. The list’s anti-obesity section ends with a plain footnote: neither Wegovy nor Zepbound will be covered for weight loss alone.^[1] That matches a long-standing state rule. Illinois’s administrative code lists anorectic drugs, meaning appetite suppressants, among pharmacy items it does not cover, using the room federal law gives every state to leave weight-loss drugs out of Medicaid.^[6][8] The list also has no row for Saxenda, orlistat, phentermine or other older weight-loss pills.^[1] Our explainer on how Medicaid treats Ozempic and Wegovy covers the federal side.

When will Illinois Medicaid pay for Wegovy or Zepbound?

For three uses that match the drugs’ newer FDA approvals. Wegovy is listed for major adverse cardiovascular events (MACE), meaning fewer heart attacks and strokes for adults who already have heart disease and carry excess weight, and for MASH with moderate to advanced fibrosis.^[1][9] Zepbound is listed for sleep apnea, which its label limits to moderate or severe cases in people who also have obesity.^[1][10] Both the Wegovy pen and the Wegovy tablets appear, as do both Zepbound pen forms, the single-dose pen and the KwikPen.^[1]

All of them are non-preferred, so expect to file a prior approval request.^[1][2] The state publishes a fee-for-service criteria document for GLP-1 and GIP drugs, effective October 1, 2026, and requests for drugs without a special form go on the regular prior approval form.^[2][3] Because that criteria file could not be read, the state’s exact requirements for the heart and MASH routes are not stated here. Expect a request to need the diagnosis that matches the label: documented heart disease, or MASH with F2 to F3 fibrosis.^[9] Our page on GLP-1s and MASH covers what the evidence shows.

What does an Illinois Medicaid plan require for Zepbound and sleep apnea?

Many Illinois Medicaid members are enrolled in one of five health plans, each with its own prior authorization pages: Aetna Better Health of Illinois, Blue Cross Community Health Plan, CountyCare, Meridian and Molina.^[3] Meridian’s sleep apnea policy is one that can be read in full, and it shows how a plan applies the state’s route.^[5]

• Moderate to severe sleep apnea confirmed by a lab or home sleep test, with an AHI (apnea-hypopnea index) of at least 15, and no central or mixed apnea.^[5]
• Age 18 or older and a BMI of at least 30.^[5]
• Ongoing symptoms despite using CPAP or another positive airway pressure device at least 4 hours a night on at least 70% of nights, or a documented reason the person cannot use one.^[5]
• A physician-directed weight program with diet, activity and behavior change.^[5]
• For people who also have type 2 diabetes, a failed trial of at least three straight months of Ozempic tablets, Trulicity, and liraglutide or Victoza first, and a medical reason for any switch from a GLP-1 they already take.^[5]
• Approval for six months at a time; since September 15, 2026, the KwikPen form is required, and Zepbound is non-preferred at Meridian.^[4][5]

Meridian’s notice repeats that GLP-1s for weight loss remain a benefit exclusion.^[4] Other plans may word their criteria differently, so the plan named on the member card is the one to ask. The CPAP rule is the requirement most likely to stop a request; our guide to insurance coverage of Zepbound for sleep apnea compares how plans handle it.

How do you request approval or appeal in Illinois?

For fee-for-service members, prescribers request prior authorization from HFS by phone at 1-800-252-8942 or by fax at 1-217-524-7264.^[2] Health plan members go through their plan’s own pharmacy prior authorization process.^[3]

Federal rules set the appeal clock for plan members: 60 days from a denial notice to appeal to the plan, then at least 90 and at most 120 days after the plan’s decision to ask for a state fair hearing.^[11][12] For a denial from the state directly, federal rules allow no more than 90 days from the mailing date, and the notice gives the exact deadline.^[13] An appeal for weight loss alone has nothing to stand on, given the footnote.^[1] Our walkthrough of prior authorization and appeals explains what to include, and the Illinois state page summarizes the Medicaid facts.

What can you do if Illinois Medicaid won’t pay?

Self-pay is what remains for weight loss alone. Lilly’s copay card terms exclude anyone enrolled in Medicaid.^[14] In the figures we track, Novo Nordisk sells most Wegovy pen doses for $349 a month to self-pay patients, and Lilly’s Zepbound KwikPen runs from $299 at the starting dose to $449 at higher doses refilled on time.^[14][15] Read each program’s terms on government coverage before enrolling, and compare them in our list of the cheapest options without insurance.